MedPage Today: DEA Emergency Scheduling Targets Three Kratom-Derived Opioids Sold in Gas Stations

Why it matters

Medical news outlet MedPage Today provides clinical context for the DEA's August 26, 2026 emergency scheduling of three kratom-derived opioids, including a documented case of a patient escalating from kratom powder to concentrated synthetic derivatives requiring medically supervised withdrawal management.

The big picture

The DEA's scheduling targets mitragynine pseudoindoxyl, MGM-15, and MGM-16 — compounds that were marketed deceptively as kratom or botanical products despite being semi-synthetic opioids significantly more potent than morphine. The Justice Department clarified that the action does not cover traditional botanical kratom, distinguishing natural leaf from chemically enhanced and manufactured opioid products.

Key findings

• Mitragynine pseudoindoxyl was linked to at least 56 overdose cases from February 2025 to May 2026, with 48 being fatal
• MGM-15 caused 17 overdose cases from February to April 2026, with 16 fatalities
• A documented patient case describes escalation from powdered kratom to 7-OH tablets to mitragynine pseudoindoxyl tablets, reaching nine 20-mg doses daily
• That patient experienced opioid withdrawal requiring 3-4 days supportive management and naltrexone depot injections
• Products were sold in child-appealing forms including flavored chewable tablets and "dried ice cream cones with ice cream" to broaden demographic appeal

What they say

Attorney General Todd Blanche stated: "These are potent opioids being manufactured and sold in consumer products, often under labels that obscure their true risks. The Justice Department is acting before these dangerous compounds become a broader threat."

Bottom line

A patient case study illustrating the escalation pathway from botanical kratom to concentrated synthetic opioids underscores why the DEA acted on an emergency basis to schedule three kratom-derived compounds.